1. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs) Expert Committee on Biological Standardization, Geneva, Switzerland. 2009 (last update 23 Oct 2009).
http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
Accessed 17 Mar 2016.
2. European Medicines Agency. Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). European Medicines Agency, London. 2014.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
Accessed 11 May 2016.
3. European Medicines Agency. European public assessment reports by type (biosimilars). European Medicines Agency, London. 2016.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter%20keywords&searchType=name&alreadyLoaded=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&jsenabled=false&searchGenericType=biosimilars&orderBy=status&pageNo=1
. Accessed 26 Apr 2016.
4. US Food and Drug Administration. FDA approves first biosimilar product Zarxio [media release]. US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. 2015 (last update 6 Mar 2015).
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm
. Accessed 11 May 2016.
5. Generics and Biosimilars Initiative (GaBi). US$67 billion worth of biosimilar patents expiring before 2020. Pro Pharma Communications International, Mol, Belgium. 2012 (last update 20 Jan 2014).
http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020
. Accessed 11 May 2016.